Sildenafil/testosterone - Freya Pharma Solutions
Alternative Names: Lybrido; Testosterone/sildenafilLatest Information Update: 18 Aug 2023
At a glance
- Originator Emotional Brain
- Developer Companion Diagnostics BV; Emotional Brain
- Class Anabolic steroids; Androstenols; Hormonal replacements; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Testosterone replacements; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Female sexual dysfunction
Most Recent Events
- 18 Aug 2023 Chemical structure information added
- 19 Jun 2023 Freya Pharma Solutions plans to file Marketing Authorization Application (MAA) for sildenafil/testosterone for Female sexual dysfunction in USA
- 19 Jun 2023 The US FDA provides positive response on the clinical development plan of sildenafil/testosterone for Female sexual dysfunction